Ms. Jennifer CHE, J.D., Vice President and Principal of Eagle IP Limited, shared about the unique IP challenges biomedical innovations in the GBA and China face. She demonstrated how a strategic approach to IP is crucial – especially at the earliest stages – to avoiding messy issues down the road. She finally touched upon what unique role Hong Kong can play to help protect and cultivate future important biomedical inventions arising out of the GBA and China.
Our Past Events
Recommended Insights
How the Chinese Patent Office Rejected a Plate-Making Method Based on Food Safety Law
19 October 2022Previously we published an article about CNIPA rejecting a patent application claiming a food that could also be used to treat or prevent diseases based on the food’s alleged non-compliance with Food Safety Law. China’s Food Safety Law includes a provision which states any use of a composition as a food must be strictly separated […]
Read more >
Breaking: China Released New Implementation Measures for the New Patent Linkage System
14 July 2021On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]
Read more >
How Smart is a "Skilled Person in the Art"?
11 April 2022Let’s start with a riddle: can you name a person who has read every book, every journal, conducted every known experiment, and is knowledgeable about every single patent prosecution / litigation in the world? The answer? A “skilled person in the art.” This person is also known as a “person having ordinary skill in the […]
Read more >
NMPA's Releases Draft Measures for Data Protection (Data Exclusivity)
4 September 2025In March 2025, China's National Medical Products Administration (NMPA) released yet another set of draft implementation measures on data protection.1 Key highlights of these new measures include the following: A Bit of History China's journey toward a comprehensive pharmaceutical data protection framework has been ongoing for over two decades, a roller coaster ride from its […]
Read more >